Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.
2.

Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women.

Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF.

Cancer Causes Control. 2018 Jul;29(7):631-642. doi: 10.1007/s10552-018-1040-1. Epub 2018 May 25.

PMID:
29802491
3.

Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype.

Derakhshandeh R, Sanadhya S, Lee Han K, Chen H, Goloubeva O, Webb TJ, Younis RH.

Oncotarget. 2018 Jan 19;9(13):11126-11144. doi: 10.18632/oncotarget.24277. eCollection 2018 Feb 16.

4.

Reply to: Point-of-care ultrasound during advanced cardiopulmonary resuscitation: Rule of art have to be respected!

Allison M, Winters ME, Huis In 't Veld OBOMA, Bostick DS, Witting M, Fisher KR, Goloubeva OG.

Resuscitation. 2018 Jan;122:e3. doi: 10.1016/j.resuscitation.2017.11.051. No abstract available.

PMID:
29254581
5.

N-glycolylneuraminic acid knockout reduces erythrocyte sequestration and thromboxane elaboration in an ex vivo pig-to-human xenoperfusion model.

Cimeno A, Hassanein W, French BM, Powell JM, Burdorf L, Goloubeva O, Cheng X, Parsell DM, Ramsoondar J, Kuravi K, Vaught T, Uluer MC, Redding E, O'Neill N, Laird C, Hershfeld A, Tatarov I, Thomas K, Ayares D, Azimzadeh AM, Pierson RN 3rd, Barth RN, LaMattina JC.

Xenotransplantation. 2017 Nov;24(6). doi: 10.1111/xen.12339. Epub 2017 Sep 22.

PMID:
28940313
6.

Ultrasound use during cardiopulmonary resuscitation is associated with delays in chest compressions.

Huis In 't Veld MA, Allison MG, Bostick DS, Fisher KR, Goloubeva OG, Witting MD, Winters ME.

Resuscitation. 2017 Oct;119:95-98. doi: 10.1016/j.resuscitation.2017.07.021. Epub 2017 Jul 25.

PMID:
28754527
7.

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z.

Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.

8.

Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue.

Dancy JG, Wadajkar AS, Schneider CS, Mauban JRH, Goloubeva OG, Woodworth GF, Winkles JA, Kim AJ.

J Control Release. 2016 Sep 28;238:139-148. doi: 10.1016/j.jconrel.2016.07.034. Epub 2016 Jul 25.

9.

Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.

Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, Bao T, Thompson J, Nightingale G, Tait NS, Nichols EM, Feigenberg SJ, Tkaczuk KH.

Am J Clin Oncol. 2018 May;41(5):508-512. doi: 10.1097/COC.0000000000000314.

PMID:
27322700
11.

Dietary Fat Intake During Adolescence and Breast Density Among Young Women.

Jung S, Goloubeva O, Klifa C, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF.

Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):918-26. doi: 10.1158/1055-9965.EPI-15-1146. Epub 2016 May 19.

12.

ReCAP: Impact of Multidisciplinary Care on Processes of Cancer Care: A Multi-Institutional Study.

Onukwugha E, Petrelli NJ, Castro KM, Gardner JF, Jayasekera J, Goloubeva O, Tan MT, McNamara EJ, Zaren HA, Asfeldt T, Bearden JD 3rd, Salner AL, Krasna MJ, Das IP, Clauser SB, Onukwugha E, Petrelli NJ, Castro KM, Gardner JF, Jayasekera J, Goloubeva O, Tan MT, McNamara EJ, Zaren HA, Asfeldt T, Bearden JD 3rd, Salner AL, Krasna MJ, Prabhu Das I, Clauser SB.

J Oncol Pract. 2016 Feb;12(2):155-6; e157-68. doi: 10.1200/JOP.2015.004200. Epub 2015 Oct 13.

13.

Venous Thromboembolic Complications of Lung Transplantation: A Contemporary Single-Institution Review.

Evans CF, Iacono AT, Sanchez PG, Goloubeva O, Kim J, Timofte I, Cheema FH, Pham SM, Griffith BP, Rajagopal K.

Ann Thorac Surg. 2015 Dec;100(6):2033-9; discussion 2039-40. doi: 10.1016/j.athoracsur.2015.05.095. Epub 2015 Sep 10.

PMID:
26363652
14.

Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors.

Weinstock C, Campassi C, Goloubeva O, Wooten K, Kesmodel S, Bellevance E, Feigenberg S, Ioffe O, Tkaczuk KH.

Springerplus. 2015 Aug 28;4:459. doi: 10.1186/s40064-015-1158-5. eCollection 2015.

15.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

16.

Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.

Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A.

Breast Cancer Res Treat. 2015 Aug;152(3):499-508. doi: 10.1007/s10549-015-3442-z. Epub 2015 Jul 2.

PMID:
26133921
17.

A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.

Schech A, Yu S, Goloubeva O, McLenithan J, Sabnis G.

Endocr Relat Cancer. 2015 Aug;22(4):645-56. doi: 10.1530/ERC-15-0168. Epub 2015 Jun 25.

PMID:
26113604
18.

The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells.

Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A.

J Cell Biochem. 2015 Oct;116(10):2210-26. doi: 10.1002/jcb.25171.

19.

Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.

Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE.

Cancer Immunol Res. 2015 May;3(5):567-74. doi: 10.1158/2326-6066.CIR-14-0188. Epub 2015 Mar 13.

20.

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE, Edelman MJ.

Cancer Immunol Immunother. 2015 Mar;64(3):367-79. doi: 10.1007/s00262-014-1640-x. Epub 2014 Dec 24.

21.

α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration.

Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS.

Cancer Res. 2015 Jan 1;75(1):203-15. doi: 10.1158/0008-5472.CAN-13-3563. Epub 2014 Dec 12.

22.

Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Lubek JE, Schumaker LM, Cullen KJ.

Head Neck. 2016 Apr;38(4):564-72. doi: 10.1002/hed.23933. Epub 2015 Jun 30.

23.

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ.

Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2.

24.

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.

Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T.

Springerplus. 2014 Jul 16;3:366. doi: 10.1186/2193-1801-3-366. eCollection 2014.

25.

Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007.

Zandberg DP, Liu S, Goloubeva OG, Schumaker LM, Cullen KJ.

Cancer Prev Res (Phila). 2015 Jan;8(1):12-9. doi: 10.1158/1940-6207.CAPR-14-0089-T. Epub 2014 Jun 10.

26.

A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey SG, Badros AZ.

Integr Cancer Ther. 2014 Sep;13(5):396-404. doi: 10.1177/1534735414534729. Epub 2014 May 26.

27.

A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast cancer.

Cao Q, Hersl J, La H, Smith M, Jenkins J, Goloubeva O, Dilsizian V, Tkaczuk K, Chen W, Jones L.

BMC Cancer. 2014 Feb 25;14:126. doi: 10.1186/1471-2407-14-126.

28.

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH.

Breast Cancer Res. 2014 Jan 29;16(1):R15. doi: 10.1186/bcr3609.

29.

Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.

Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, Fulton A.

Breast Cancer Res Treat. 2014 Jan;143(1):19-31. doi: 10.1007/s10549-013-2779-4. Epub 2013 Nov 27.

30.

HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.

Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH.

Mol Cancer Ther. 2013 Dec;12(12):2804-16. doi: 10.1158/1535-7163.MCT-13-0345. Epub 2013 Oct 3.

31.
32.

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD.

Cancer Prev Res (Phila). 2012 Apr;5(4):544-52. doi: 10.1158/1940-6207.CAPR-11-0228. Epub 2012 Mar 31.

33.

Analysis of local control in patients receiving IMRT for resected pancreatic cancers.

Yovino S, Maidment BW 3rd, Herman JM, Pandya N, Goloubeva O, Wolfgang C, Schulick R, Laheru D, Hanna N, Alexander R, Regine WF.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):916-20. doi: 10.1016/j.ijrobp.2011.08.026. Epub 2012 Jan 25.

34.

Detection of lesions during capsule endoscopy: physician performance is disappointing.

Zheng Y, Hawkins L, Wolff J, Goloubeva O, Goldberg E.

Am J Gastroenterol. 2012 Apr;107(4):554-60. doi: 10.1038/ajg.2011.461. Epub 2012 Jan 10.

PMID:
22233695
35.

Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial.

Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ.

Cancer. 2012 Apr 1;118(7):1811-7. doi: 10.1002/cncr.26485. Epub 2011 Aug 25.

36.

Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors.

Mahmood U, Koshy M, Goloubeva O, Suntharalingam M.

Arch Otolaryngol Head Neck Surg. 2011 Oct;137(10):1025-30. doi: 10.1001/archoto.2011.158.

PMID:
22006781
37.

Antimetastatic activity isolated from Colocasia esculenta (taro).

Kundu N, Campbell P, Hampton B, Lin CY, Ma X, Ambulos N, Zhao XF, Goloubeva O, Holt D, Fulton AM.

Anticancer Drugs. 2012 Feb;23(2):200-11. doi: 10.1097/CAD.0b013e32834b85e8.

38.

Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients.

Tkaczuk KH, Tait NS, Ioffe O, Tan M, Goloubeva OG, Lesko SA, Deamond SF, Zhou D, Lum ZP, Sutula MJ, Van Echo D, Ts'o PO.

Discov Med. 2011 Jul;12(62):33-40.

39.

Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.

Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM.

Breast Cancer Res Treat. 2012 Apr;132(3):1001-8. doi: 10.1007/s10549-011-1675-z. Epub 2011 Jul 15.

40.

Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.

Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1845-50. doi: 10.1016/j.ijrobp.2011.02.062. Epub 2011 May 19.

41.

High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT.

Neuner G, Mohiuddin MM, Vander Walde N, Goloubeva O, Ha J, Yu CX, Regine WF.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1642-9. doi: 10.1016/j.ijrobp.2011.01.065. Epub 2011 Apr 29.

PMID:
21531514
42.

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ.

Ann Oncol. 2011 May;22(5):1071-7. doi: 10.1093/annonc/mdr006. Epub 2011 Feb 11.

43.

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM.

Cancer Res. 2011 Mar 1;71(5):1893-903. doi: 10.1158/0008-5472.CAN-10-2458. Epub 2011 Jan 18.

44.

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group.

Lancet Oncol. 2011 Feb;12(2):153-9. doi: 10.1016/S1470-2045(10)70279-5. Epub 2011 Jan 11.

45.

Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.

Hussain A, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Engstrom C, Dawson N, Amin P, Kwok Y.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):167-74. doi: 10.1016/j.ijrobp.2010.09.009. Epub 2010 Oct 30.

PMID:
21036487
46.

Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.

Ma X, Kundu N, Ioffe OB, Goloubeva O, Konger R, Baquet C, Gimotty P, Reader J, Fulton AM.

Mol Cancer Res. 2010 Oct;8(10):1310-8. doi: 10.1158/1541-7786.MCR-10-0003. Epub 2010 Sep 21.

47.

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM.

Br J Cancer. 2010 Sep 28;103(7):1001-7. doi: 10.1038/sj.bjc.6605882. Epub 2010 Sep 14.

48.

Impact of neoadjuvant radiation on survival in stage III non-small-cell lung cancer.

Koshy M, Goloubeva O, Suntharalingam M.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1388-94. doi: 10.1016/j.ijrobp.2009.12.066. Epub 2010 Jun 3.

PMID:
20605359
49.

Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A.

Mol Cancer Ther. 2010 Jan;9(1):46-56. doi: 10.1158/1535-7163.MCT-09-0696. Epub 2010 Jan 6.

50.

beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.

Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR.

J Clin Oncol. 2009 Dec 20;27(36):6222-8. doi: 10.1200/JCO.2009.23.0953. Epub 2009 Nov 16.

PMID:
19917838

Supplemental Content

Loading ...
Support Center